Full-Time

Senior Accountant

Posted on 8/30/2024

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

51-200 employees

Develops treatments for neurodegenerative diseases

Biotechnology
Healthcare

Senior, Expert

Remote in USA

Must reside and work within the United States in a state where Amylyx currently does business.

Category
Budget Analysis
Financial Accounting
Management Accounting
Accounting
Requirements
  • 5+ years of relevant accounting experience
  • Bachelor’s degree in accounting
  • Intermediate proficiency with Microsoft Office Products (advanced Excel preferred)
Responsibilities
  • Prepare monthly account reconciliations, resolve discrepancies, and ensure accurate reporting
  • Participate in monthly PO accrual meetings with business owners and prepare required accrual journal entries
  • Reconcile cash transactions in a timely manner
  • Prepare intercompany markup calculations and journal entries
  • Calculate T&E accruals
  • Assist with the preparation of the actual vs. actual analysis
  • Manage month-end close tasks to ensure timely and accurate completion
  • Support internal SOX and external audit requirements
  • Assist in the interim and year-end audit process
  • Participate in process improvement activities, including enhancing current financial processes and suggesting areas for improvement
  • Support the senior management team with various analyses and ad hoc projects
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials, including the CENTAUR ALS trial, which showed significant benefits for ALS patients through a randomized, double-blind, placebo-controlled study. They are also conducting the PEGASUS trial to assess AMX0035's safety and effectiveness for Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.

Company Stage

IPO

Total Funding

$166.7M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

-13%

1 year growth

5%

2 year growth

8%
Simplify Jobs

Simplify's Take

What believers are saying

  • Positive CENTAUR trial results boost AMX0035's credibility for ALS treatment.
  • Growing interest in combination therapies aligns with Amylyx's AMX0035 strategy.
  • FDA's expedited approval initiatives could accelerate Amylyx's drug pipeline.

What critics are saying

  • Relyvrio's Phase III trial failure impacts Amylyx's reputation and future approvals.
  • Avexitide acquisition may strain finances if Phase 3 trials underperform.
  • New CCO Dan Monahan might disrupt operations with strategic shifts.

What makes Amylyx Pharmaceuticals unique

  • Amylyx focuses on neurodegenerative diseases like ALS and Alzheimer's, unlike many competitors.
  • AMX0035 combines sodium phenylbutyrate and taurursodiol, a unique approach in treatment.
  • Amylyx engages in community awareness campaigns, enhancing its brand and patient support.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

INACTIVE